

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



GenFleet Therapeutics (Shanghai) Inc.

勁方醫藥科技(上海)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2595)

(1) POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON FEBRUARY 9, 2026; AND (2) ABOLISHMENT OF THE SUPERVISORY COMMITTEE AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION

References are made to (i) the circular (the “**Circular**”) and (ii) the notice (the “**Notice**”) both dated January 23, 2026 issued by GenFleet Therapeutics (Shanghai) Inc. (the “**Company**”) in relation to the extraordinary general meeting of the Company (the “**EGM**”). Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Circular.

THE EXTRAORDINARY GENERAL MEETING

The Board is pleased to announce that the EGM was held at 10:00 a.m. on Monday, February 9, 2026 at the meeting room of the Company at Room 212, Building A, 1206 Zhangjiang Road, (Shanghai) Pilot Free Trade Zone, PRC.

As at the time of the EGM, the Company had a total of 370,366,630 Shares in issue, comprising 338,029,020 H Shares and 32,337,610 Unlisted Shares. Among these, none of the H Shares or Unlisted Shares was held as treasury Shares (including any treasury Shares held or deposited with the Central Clearing and Settlement System operated by Hong Kong Securities Clearing Company Limited), and no voting rights attached to the treasury Shares may be exercised at the EGM. The total number of Shares entitling the holders to attend and vote for or against all the resolutions in the Notice proposed at the EGM was 370,366,630. There were no repurchased Shares which are pending cancellation and accordingly should be excluded from the total number of issued Shares for the purposes of the EGM. There were no Shares entitling the holder to attend and abstain from voting in favour of any resolutions proposed for consideration and approval by the Shareholders at the EGM as set out in Rule 13.40 of the Listing Rules. No Shareholders were required to abstain from voting at the EGM under the Listing Rules and none of the Shareholders has stated their intention in the Circular to vote against or to abstain from voting on any of the resolutions proposed for consideration and approval by the Shareholders at the EGM.

The EGM was legally and validly convened in compliance with the requirements of the Company Law of the PRC, the relevant laws and regulations of the PRC, the Listing Rules and the articles of association of the Company. All Directors, namely, Dr. Qiang LU, Dr. Jiong LAN, Ms. ZHANG Wei, Mr. ZHU Jingyang, Ms. TAO Sha, Ms. Christine Shaohua LU-WONG, Dr. ZHOU Demin and Mr. LI Bo, attended the EGM in person or by electronic means.

The Company's H Share Registrar, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer for the purpose of vote-taking at the EGM.

All the resolutions as set out in the Notice were put to vote by way of poll by the Shareholders (including their proxies and authorised representatives) at the EGM.

POLL RESULTS OF THE EGM

The poll results of the proposed resolutions (the “**Resolutions**”) at the EGM were as follows:

SPECIAL RESOLUTIONS ⁽¹⁾		Number of votes (%)		
		For	Against	Abstain
1.	To consider and approve the proposed adoption of the H Share Option Scheme.	162,763,808 (93.670208%)	10,998,812 (6.329792%)	0 (0.000000%)
2.	To consider and approve the proposed adoption of the H Share Incentive Scheme.	162,763,808 (93.670208%)	10,998,812 (6.329792%)	0 (0.000000%)
3.	To consider and approve the proposed Scheme Limit.	166,080,828 (95.579146%)	7,681,792 (4.420854%)	0 (0.000000%)
4.	To consider and approve the proposed Service Provider Sublimit.	157,810,717 (90.819715%)	15,951,903 (9.180285%)	0 (0.000000%)
5.	To consider and approve the proposed authorization to the Board and/or the authorised person(s) to handle matters pertaining to the H Share Option Scheme and H Share Incentive Scheme.	163,917,833 (94.334347%)	9,844,787 (5.665653%)	0 (0.000000%)
6.	To consider and approve the proposed granting of the general mandate to the Board to repurchase H Shares.	170,445,600 (98.091062%)	3,317,020 (1.908938%)	0 (0.000000%)
7.	To consider and approve the Proposed Amendments to the Articles of Association and abolishment of the Supervisory Committee.	173,762,620 (100.000000%)	0 (0.000000%)	0 (0.000000%)

Note:

- (1) Please refer to the Circular for the full text of the Resolutions. Special resolutions shall be passed by votes representing at least two-thirds of the voting rights held by the Shareholders (including proxies thereof) attending the EGM.

As more than two-thirds of the votes from the Shareholder (including their proxies and authorized representatives) were cast in favour of the special resolutions no.1 to no.7, the special resolutions no.1 to no.7 were duly passed as special resolutions of the Company by way of poll at the EGM.

ABOLISHMENT OF THE SUPERVISORY COMMITTEE AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION

A special resolution was passed by the Shareholders at the EGM to approve the abolishment of the Supervisory Committee and amendments to the Articles of Association. Accordingly, effective from February 9, 2026, the Company will no longer have the Supervisory Committee, and the current members of the Supervisory Committee shall cease to hold office as Supervisors; and the amended Articles of Association shall become effective from the date of the EGM. The full text of the amended Articles of Association will be published on the websites of the Company (www.genfleet.com) and the Stock Exchange (www.hkexnews.hk).

By order of the Board
GenFleet Therapeutics (Shanghai) Inc.
Dr. Qiang LU
Chairman and Executive Director

Hong Kong, February 9, 2026

As at the date of this notice, the Board of the Company comprises: (i) Dr. Qiang LU, Dr. Jiong LAN and Ms. ZHANG Wei as executive Directors; (ii) Mr. ZHU Jingyang and Ms. TAO Sha as non-executive Directors; and (iii) Ms. Christine Shaohua LU-WONG, Dr. ZHOU Demin and Mr. LI Bo as independent non-executive Directors.